Skip to main content
Pfizer's Fragmin OK'd for pediatric symptomatic VTE

Pfizer's Fragmin, or dalteparin sodium, was approved by the FDA to lessen the recurrence of symptomatic venous thromboembolism in pediatric patients at least 1 month old. The drug was first approved for adult patients with certain types of angina, deep vein thrombosis and symptomatic VTE.

Full Story: